SCHEDULE: Major Investor Reduces Stake in Therapeutics Firm

FMR LLC and Abigail P. Johnson have reduced their beneficial ownership in BICARA THERAPEUTICS INC to 4.7% of common stock, triggering a Schedule 13G amendment.

Summary

• FMR LLC and Abigail P. Johnson filed an Amendment No. 2 to Schedule 13G, reporting their beneficial ownership of BICARA THERAPEUTICS INC common stock.
• As of June 30, 2025, they collectively beneficially own 2,538,404 shares of common stock, which represents 4.7% of the class.
• This filing indicates a reduction in their stake, as it falls below the 5% threshold that typically requires more frequent reporting.
• FMR LLC holds sole voting power over 2,538,085 shares and sole dispositive power over 2,538,404 shares.
• Abigail P. Johnson holds sole dispositive power over 2,538,404 shares.
• The reporting persons certified that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 4

Explanation: The reduction of a significant beneficial ownership stake by a major institutional investor like FMR LLC, falling below the 5% threshold, is generally perceived as a negative signal, potentially indicating a lack of conviction or a strategic divestment.

Negatives

• The reduction of a significant beneficial ownership stake by a major institutional investor like FMR LLC, falling below the 5% threshold, may be perceived negatively by the market.
• This reduction could signal a decrease in confidence or a strategic reallocation of capital away from BICARA THERAPEUTICS INC.

Risks

• Potential negative market perception and investor sentiment due to a large institutional investor reducing its stake.
• Reduced institutional support for the company's stock, which could impact liquidity and valuation.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reflects a change in institutional investment within the biotechnology and pharmaceutical sector. Large institutional investors frequently adjust their positions based on market conditions, company performance, or portfolio rebalancing. A reduction below the 5% threshold means the investor is no longer required to report changes as frequently, which can reduce transparency for other investors.

Related Party Transactions

• Abigail P. Johnson is identified as a Director, the Chairman, and the Chief Executive Officer of FMR LLC.
• Members of the Johnson family, including Abigail P. Johnson, are the predominant owners of Series B voting common shares of FMR LLC, representing 49% of its voting power.

Stakeholder Impact

• Shareholders: May interpret the reduction in institutional ownership as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• Company Management: Might face questions regarding the reasons for the divestment by a major investor.

Key Dates

Keywords

BICARA THERAPEUTICS INC, FMR LLC, Abigail P. Johnson, Schedule 13G, beneficial ownership, common stock, institutional investment, stake reduction, SEC filing, biotechnology, pharmaceuticals